NTLA - Intellia Therapeutics, Inc.

QQQ $ 446.25 $ -12.35 (-2.68 %)

DIA $ 404.28 $ -3.99 (-0.98 %)

SPY $ 539.90 $ -9.25 (-1.68 %)

TLT $ 99.49 $ -0.01 (-0.01 %)

GLD $ 230.65 $ -1.72 (-0.74 %)

Previous Close

$ 19.72

Open

Bid

$ 19.72 x 100

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 19.37 - $ 38.71

Volume

1,418,935

Average Volume

Market Cap

Beta (5Y Monthly)

$ 1.58

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-08-2024	06-30-2024	10-Q
2	05-09-2024	03-31-2024	10-Q
3	02-22-2024	12-31-2023	10-K
4	11-09-2023	09-30-2023	10-Q
5	08-03-2023	06-30-2023	10-Q
6	05-04-2023	03-31-2023	10-Q
7	02-23-2023	12-31-2022	10-K
8	11-03-2022	09-30-2022	10-Q
9	08-04-2022	06-30-2022	10-Q
10	05-05-2022	03-31-2022	10-Q
11	02-24-2022	12-31-2021	10-K
12	11-04-2021	09-30-2021	10-Q
13	08-05-2021	06-30-2021	10-Q
14	05-06-2021	03-31-2021	10-Q
15	02-26-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-06-2020	06-30-2020	10-Q
18	05-07-2020	03-31-2020	10-Q
19	02-27-2020	12-31-2019	10-K
20	10-31-2019	09-30-2019	10-Q
21	08-01-2019	06-30-2019	10-Q
22	05-02-2019	03-31-2019	10-Q
23	02-27-2019	12-31-2018	10-K
24	10-31-2018	09-30-2018	10-Q
25	08-01-2018	06-30-2018	10-Q
26	05-01-2018	03-31-2018	10-Q
27	03-14-2018	12-31-2017	10-K
28	10-31-2017	09-30-2017	10-Q
29	08-01-2017	06-30-2017	10-Q
30	05-02-2017	03-31-2017	10-Q
31	03-14-2017	12-31-2016	10-K
32	11-01-2016	09-30-2016	10-Q
33	08-04-2016	06-30-2016	10-Q
34	06-03-2016	03-31-2016	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Expert Ratings For Intellia Therapeutics
08/12/2024 16:01:14

JP Morgan Maintains Overweight on Intellia...
08/12/2024 14:36:44

JP Morgan analyst Brian Cheng maintains Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and lowers the price target fr...

RBC Capital Maintains Outperform on Intell...
08/09/2024 19:43:27

RBC Capital analyst Luca Issi maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and lowers the price target fr...

Intellia Therapeutics Cash, Cash Equivalen...
08/08/2024 11:39:29

Intellia Therapeutics Q2 2024 GAAP EPS $(1...
08/08/2024 11:37:41

Intellia Therapeutics Receives UK MHRA Aut...
07/30/2024 11:41:49

Intellia Therapeutics Receives Authorizati...
07/30/2024 11:41:11

bank-of-new-york-mellon-posts-upbeat-earnings-joins-archer-aviation-rivian-automotive-and-other-big-stocks-moving-higher-on-friday

Bank of New York Mellon Posts Upbeat Earni...
07/12/2024 14:27:17

cathie-woods-ark-invest-dumps-another-325m-worth-of-tesla-shares-amid-searing-q2-deliveries-rally

Cathie Wood's Ark Invest Dumps Another $3....
07/04/2024 01:52:52

cathie-woods-ark-invest-sells-tesla-shares-worth-145m-amid-rally-driven-by-q2-delivery-numbers-picks-up-palantir-shares-again-today

Cathie Wood's Ark Invest Sells Tesla Share...
07/03/2024 02:26:04

Canaccord Genuity Maintains Buy on Intelli...
06/27/2024 13:38:05

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $73 price target.

cathie-woods-ark-invest-acquires-73m-worth-of-shares-in-this-promising-netflix-competitor-sells-off-coinbase-stock-amid-bitcoin-slump

Cathie Wood's Ark Invest Acquires $7.3M Wo...
06/27/2024 03:33:17

On Wednesday, Cathie Wood-led Ark Invest made significant trades in Roku Inc (NASDAQ:ROKU) and Coinbase Global Inc (NASDAQ:COIN...

Intellia Therapeutics Named Edward Dulac O...
06/26/2024 11:32:24

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine wi...

Intellia Therapeutics Presents Data On Red...
06/25/2024 19:32:54

First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 ...

Cantor Fitzgerald Reiterates Overweight on...
06/24/2024 18:30:10

Cantor Fitzgerald analyst Rick Bienkowski reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and maintains $65...

Unveiling 6 Analyst Insights On Intellia T...
06/24/2024 18:01:29

Truist Securities Maintains Buy on Intelli...
06/24/2024 17:34:40

Truist Securities analyst Joon Lee maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $120 price target.

rxo-alnylam-pharmaceuticals-and-other-big-stocks-moving-lower-in-mondays-pre-market-session

RXO, Alnylam Pharmaceuticals And Other Big...
06/24/2024 11:54:53

5-biotech-stocks-with-key-catalysts-this-week-merck-intellia-verona-and-more

5 Biotech Stocks With Key Catalysts This W...
06/24/2024 08:51:47

Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.

Cantor Fitzgerald Reiterates Overweight on...
06/18/2024 14:12:26

Cantor Fitzgerald analyst Rick Bienkowski reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and maintains $65...